Bioptigen has been awarded a $458,000 strategic growth loan from the North Carolina Biotechnology Center to support clinical validation of the company’s intrasurgical optical coherence tomography (OCT) imaging system.

The EnFocus system will provide 3-D visualization simultaneous with, and co-registered to, images from surgical ophthalmic microscopes. The device is intended to enable precision surgery with better patient outcomes and reduce the need for postsurgical follow-up procedures.

In September, Bioptigen received grants totaling $1.72 million from the National Eye Institute for development of the technology.

The company’s OCT imaging devices are sold to pediatric and surgical ophthalmology clinics and hospitals, and academic ophthalmology research centers globally.

For more information, visit www.bioptigen.com.